Gaudium IVF and Women Health Ltd (GAUDIUMIVF) Share Price & Fundamentals

What we do

Gaudium IVF and Women Health Ltd offers specialized fertility and reproductive health services including IVF, ICSI, IUI, male infertility treatments, and genetic testing.

Founded in

2,015

Market share

Growing presence with hub-and-spoke model across multiple Indian states, including expansions in Jammu & Kashmir and Karnataka.

Problem solved

Addresses infertility challenges for both males and females with advanced treatments and holistic reproductive healthcare.

Top clients or who we serve

B2C focus serving couples facing fertility and reproductive health issues across India.

Key management

Founded by Dr. Manika Khanna, a specialist trained in gynecological endoscopic surgery with international expertise.

Our journey and innovations

Started operations in 2019, acquired a proprietary firm in 2021, expanded centers in 2024, and launched IPO in 2026 raising Rs 165 crore.

Where we operate

India with centers in Jammu & Kashmir, Karnataka, and other states following hub-and-spoke model.

Top products or what we offer

IVF, ICSI, IUI, ovulation induction, fertility preservation, laparoscopic surgeries, genetic testing including PGT.

Top brands

-

Raw materials needed

-

Raw materials supplier

-

Recurring vs cyclical contribution

Revenue mainly from cyclical medical services linked to fertility treatments.

Our industry position

Emerging player with expanding footprint in India's specialized fertility healthcare sector.

Financial highlights

Revenue of Rs 70.72 crore and net profit of Rs 19.13 crore for fiscal year ending March 2025.

Geographical revenue split

-

Order book

-

Whats driving growth

Expansion into new regions, advanced treatment offerings, and rising demand for fertility solutions.

Our future plans

Scaling operations with new centers, enhancing treatment technology, and leveraging IPO funds for growth.

Our green promise

-

Our people and values

-

Key challenges ahead

Regulatory adherence, market competition, and sustaining high treatment success rates.

Interesting facts

First IPO in this niche healthcare segment raising Rs 165 crore in 2026.

Risks and strategy

Mitigating health compliance risks with advanced medical protocols and expanding geographic presence for competitive advantage.